Topline BE BOLD: Bimekizumab Reported Superior to Risankizumab for ACR50 at Week 16

UCB reported topline results from BE BOLD, a head-to-head study in adults with active psoriatic arthritis, with ACR50 at Week 16 described as the primary endpoint. In the same announcement, the sponsor said bimekizumab was statistically superior to risankizumab on that Week 16 endpoint.

The trial was multicenter, randomized, double-blind, risankizumab-controlled, and parallel-group, with adults assigned to one of two active biologic arms in a head-to-head framework. It had an enrolled sample size of 553 adult participants with active psoriatic arthritis. Across these descriptions, BE BOLD is framed as a blinded, active-comparator study comparing bimekizumab and risankizumab in an adult active PsA cohort.

For efficacy, the sponsor stated that ACR50 at Week 16 was the primary endpoint and that the bimekizumab arm achieved statistical superiority versus risankizumab at that timepoint. UCB reported that bimekizumab was generally well tolerated through Week 16, with no new safety signals observed.

The sponsor also said the full BE BOLD results are intended for submission for presentation at a forthcoming international scientific congress.